We are live on ! Find out more
SGYP

Synergy Pharmaceuticals
SGYP

Delisted

SGYP was delisted on the 7th of March, 2019.

85 hedge funds and large institutions have $143M invested in Synergy Pharmaceuticals in 2015 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 30 increasing their positions, 19 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

159% more capital inflows, than outflows

Capital inflows: $32.1M | Capital outflows: $12.4M

58% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 19

54% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 13

16% more call options, than puts

Call options by funds: $1.9M | Put options by funds: $1.63M

9% more funds holding

Funds holding: 78 → 85 (+7)

6.08% more ownership

Funds ownership: 25.87% → 31.95% (+6.1%)

Holders
85
Holders Change
+7
Holders Change %
+8.97%
% of All Funds
2.25%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
20
Increased
30
Reduced
19
Closed
13
Calls
$1.9M
Puts
$1.63M
Net Calls
+$262K
Net Calls Change
+$346K

SGYP Hedge Fund Activity: Q1 2015 in Review

85 of the 3,770 institutional investors tracked by Wall St. Rank reported a position in Synergy Pharmaceuticals (SGYP) for Q1 2015, worth a combined $143M — up 87% from $76.2M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new SGYP positions and 13 closed out — a net gain of 7 holders — while 30 added to existing stakes and 19 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $10.1M. The largest seller was Fidelity Investments, exiting entirely with an estimated $5.15M sold.

  • 85 institutional investors held Synergy Pharmaceuticals (SGYP) as of Q1 2015, up from 78 in Q4 2014.
  • Funds reported $143M of Synergy Pharmaceuticals stock for Q1 2015, up 87% quarter-over-quarter.
  • 20 funds opened new Synergy Pharmaceuticals positions in Q1 2015 and 13 closed out, a net change of +7 holders.
  • The largest Synergy Pharmaceuticals buyer in Q1 2015 was OrbiMed, an estimated $10.1M added.
  • The largest Synergy Pharmaceuticals seller in Q1 2015 was Fidelity Investments, an estimated $5.15M sold.

Based on aggregated 13F filings for Q1 2015.